5-氨基-2-吡嗪酸 | 40155-43-9

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - 其他氨基酸衍生物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 5-氨基-2-吡嗪酸
• 中文别名: 5-氨基吡嗪-2-羧酸；2-氨基-5-吡嗪羧酸
• 英文名称: 5-aminopyrazine-2-carboxylic acid
• 英文别名: 5-Amino-pyrazin-2-carbonsaeure
• CAS: 40155-43-9
• 化学式: C₅H₅N₃O₂
• 分子量: 139.114
• InChiKey: FMEFOOOBIHQRMK-UHFFFAOYSA-N

物化性质

• 熔点：
  283 °C (decomp)
• 沸点：
  431.8±45.0 °C(Predicted)
• 密度：
  1.533±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.7
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  89.1
• 氢给体数：
  2
• 氢受体数：
  5

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  2-8°C

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 5-Aminopyrazine-2-carboxylic acid
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 5-Aminopyrazine-2-carboxylic acid
CAS number: 40155-43-9

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C5H5N3O2
Molecular weight: 139.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  5-氨基-2-吡嗪酸 在 硫酸 、 potassium carbonate 作用下， 以 甲醇 、 正己烷 为溶剂， 反应 8.0h， 生成
  参考文献：
  名称：

  乙吡嗪衍生物：作为抗感染药和非生物兴奋剂的合成和生物学评估。

  摘要：

  由于增加的抗菌素耐药性，结核分枝杆菌（Mtb）引起的结核病（TB）已成为致命的感染。这个严重的问题推动了全球范围内努力发现对Mtb有效的新药。一个研究领域是作为潜在抗结核药物的吡嗪酰胺衍生物的合成和评价。在本文中，我们报告了一系列脲基吡嗪的合成和生物学评估。通过使烷基/芳基异氰酸酯与氨基吡嗪或与5-氨基吡嗪-2-羧酸丙酯反应来合成化合物。使用具有聚焦场的CEM Discover微波反应器在加压小瓶中进行反应。评估了产品的纯度和化学结构，并在体外测试了最终化合物的抗分枝杆菌，抗菌和抗真菌活性。5-（3-苯基脲基）吡嗪-2-羧酸丙酯（化合物4，MICMtb = 1.56μg/ mL，5.19μM）和5-（3-（4-甲氧基苯基）脲基）吡嗪-2-羧酸丙酯（化合物6， MICMtb = 6.25μg/ mL，18.91μM）对Mtb H37Rv具有高抗分枝杆菌活性，对HepG2细胞系无体外细胞毒性。

  DOI：

  10.3390/molecules22101797
• 作为产物：
  描述：

  5-氯吡嗪-2-羧酸 在 ammonium hydroxide 作用下， 反应 0.5h， 以70%的产率得到5-氨基-2-吡嗪酸
  参考文献：
  名称：

  乙吡嗪衍生物：作为抗感染药和非生物兴奋剂的合成和生物学评估。

  摘要：

  由于增加的抗菌素耐药性，结核分枝杆菌（Mtb）引起的结核病（TB）已成为致命的感染。这个严重的问题推动了全球范围内努力发现对Mtb有效的新药。一个研究领域是作为潜在抗结核药物的吡嗪酰胺衍生物的合成和评价。在本文中，我们报告了一系列脲基吡嗪的合成和生物学评估。通过使烷基/芳基异氰酸酯与氨基吡嗪或与5-氨基吡嗪-2-羧酸丙酯反应来合成化合物。使用具有聚焦场的CEM Discover微波反应器在加压小瓶中进行反应。评估了产品的纯度和化学结构，并在体外测试了最终化合物的抗分枝杆菌，抗菌和抗真菌活性。5-（3-苯基脲基）吡嗪-2-羧酸丙酯（化合物4，MICMtb = 1.56μg/ mL，5.19μM）和5-（3-（4-甲氧基苯基）脲基）吡嗪-2-羧酸丙酯（化合物6， MICMtb = 6.25μg/ mL，18.91μM）对Mtb H37Rv具有高抗分枝杆菌活性，对HepG2细胞系无体外细胞毒性。

  DOI：

  10.3390/molecules22101797

文献信息

• [EN] NOVEL GLP-1 RECEPTOR MODULATORS<br/>[FR] NOUVEAUX MODULATEURS DU RÉCEPTEUR DU GLP-1
  申请人：CELGENE INT II SARL

  公开号：WO2018200833A1

  公开（公告）日：2018-11-01

  Compounds are provided that modulate the glucagon-like peptide 1 (GLP-1) receptor, as well as products containing such compounds, and methods of their use and synthesis. Such compounds have the structure of Formula (I) below: (I) or pharmaceutically acceptable salts thereof, wherein A, J, W1, Y, Z, R1, R2, R3 and R4 are as defined herein.

  提供了调节胰高血糖素样肽1（GLP-1）受体的化合物，以及含有这些化合物的产品，以及它们的使用和合成方法。这些化合物具有如下的结构式（I）或其药用盐，其中A、J、W1、Y、Z、R1、R2、R3和R4的定义如下。
• [EN] HETEROARYLS AMIDE DERIVATIVES AND THEIR USE AS GLUCOKINASE ACTIVATORS<br/>[FR] DÉRIVÉS D'AMIDES D'HÉTÉROARYLES ET LEUR UTILISATION COMME ACTIVATEURS DE LA GLUCOKINASE
  申请人：PFIZER

  公开号：WO2010029461A1

  公开（公告）日：2010-03-18

  The present invention provides Formula (1A) compounds that act as glucokinase activators; pharmaceutical compositions thereof; and methods of treating diseases, disorders, or conditions mediated by glucokinase. X, Y, Z, R1, R2, R3, and R4 are as described herein.

  本发明提供了作为葡糖激酶激活剂的式(1A)化合物；其药物组合物；以及治疗由葡糖激酶介导的疾病、紊乱或状况的方法。其中，X、Y、Z、R1、R2、R3和R4如本文所述。
• Substituted imidazopyrimidine, imidazopyrazine and imidazopyridazine derivatives as melanocortin-4 receptor modulators
  申请人：Santhera Pharmaceuticals (Schweiz) AG

  公开号：EP2103614A1

  公开（公告）日：2009-09-23

  The present invention relates to substituted imidazopyrimidine derivatives, substituted imidazopyrazine derivatives and substituted imidazopyridazine derivatives as melanocortin-4 receptor (MC-4R) modulators, in particular as melanocortin 4 receptor antagonists. The antagonists are useful for the treatment of disorders and diseases such as cancer cachexia, muscle wasting, anorexia, emesis, anxiety, amytrophic lateral sclerosis and depression.

  本发明涉及取代咪唑吡啶衍生物、取代咪唑吡嗪衍生物和取代咪唑吡啶二嗪衍生物作为黑色素皮质素-4受体（MC-4R）调节剂，特别是作为黑色素皮质素4受体拮抗剂。这些拮抗剂可用于治疗癌症恶病质、肌肉消耗、厌食症、呕吐、焦虑、肌萎缩性侧索硬化和抑郁等疾病和疾病。
• CDK类小分子抑制剂的化合物及其用途
  申请人：广东东阳光药业有限公司

  公开号：CN105294737B

  公开（公告）日：2019-02-12

  本发明涉及新的作为CDK类小分子抑制剂的化合物(如式(I)所示)及其用途，还涉及含有上述化合物的药物组合物，以及这些化合物和组合物在治疗过度增殖性紊乱的疾病的用途。本发明的新化合物是有力的细胞周期蛋白依赖性激酶4(cdk4)或细胞周期蛋白依赖性激酶6(cdk6)抑制剂。
• Substituted Heteroaryls
  申请人：Benbow John William

  公开号：US20100063063A1

  公开（公告）日：2010-03-11

  The present invention provides Formula (1A) compounds that act as glucokinase activators; pharmaceutical compositions thereof; and methods of treating diseases, disorders, or conditions mediated by glucokinase. X, Y, Z, R 1 , R 2 , R 3 , and R 4 are as described herein.

  本发明提供了作为葡萄糖激酶激活剂的化合物Formula（1A）；其制药组合物；以及治疗由葡萄糖激酶介导的疾病、疾病或情况的方法。X、Y、Z、R1、R2、R3和R4如本文所述。